POTENCIAL DO Δ9-TETRAHIDROCANABIVARINA NA REGULAÇÃO DO PESO CORPORAL
DOI:
https://doi.org/10.64956/gm-unifacol.v1i2.47Palavras-chave:
Cannabis sativa, THCV, Canabinoides, Obesidade, EmagrecimentoResumo
A obesidade, caracterizada pelo acúmulo excessivo de gordura e inflamação crônica de baixo grau, representa um desafio global à saúde pública. Intervenções incluem mudanças no estilo de vida, com farmacoterapia secundária. Cannabis sativa tem despertado interesse terapêutico, especialmente por seus fitocanabinoides, como o Δ9-tetrahidrocanabivarina (THCV). O THCV atua principalmente como antagonista do receptor CB1 e agonista parcial do CB2, modulando apetite, metabolismo e respostas inflamatórias. Estudos pré-clínicos e clínicos demonstram que o THCV melhora tolerância à glicose, sensibilidade à insulina, reduz triglicerídeos hepáticos e promove perda de peso, sem efeitos adversos significativos, evidenciando seu potencial no tratamento da obesidade e síndrome metabólica.
Referências
ABIOYE, Amos et al. Δ9-TETRAHYDROCANNABIVARIN (THCV): A COMMENTARY ON POTENTIAL THERAPEUTIC BENEFIT FOR THE MANAGEMENT OF OBESITY AND DIABETES. Journal of Cannabis Research, v. 2, n. 1, p. 6, 2020.
CAVALHEIRO, Emanuel Kennedy Ferreira et al. CANNABIS SATIVA AS A TREATMENT FOR OBESITY: FROM ANTI-INFLAMMATORY INDIRECT SUPPORT TO A PROMISING METABOLIC RE-ESTABLISHMENT TARGET. Cannabis and Cannabinoid Research, v. 7, n. 2, p. 135–151, 2022.
CHARYTONIUK, Tomasz et al. THE ENDOCANNABINOID SYSTEM AND PHYSICAL ACTIVITY—A ROBUST DUO IN THE NOVEL THERAPEUTIC APPROACH AGAINST METABOLIC DISORDERS. International Journal of Molecular Sciences, v. 23, n. 6, 2022.
COTA, Daniela et al. ENDOGENOUS CANNABINOID SYSTEM AS A MODULATOR OF FOOD INTAKE. International Journal of Obesity and Related Metabolic Disorders, v. 27, n. 3, p. 289–301, mar. 2003.
COTA, Daniela. ROLE OF THE ENDOCANNABINOID SYSTEM IN ENERGY BALANCE REGULATION AND OBESITY. Frontiers of Hormone Research, v. 36, p. 135–145, 2008.
DOUMAR, Hanane et al. EXPLORING THE DIVERSITY OF CANNABIS CANNABINOID AND NON-CANNABINOID COMPOUNDS AND THEIR ROLES IN ALZHEIMER’S DISEASE: A REVIEW. IBRO Neuroscience Reports, v. 18, p. 96–119, ago. 2024.
ENGELI, Stefan. DYSREGULATION OF THE ENDOCANNABINOID SYSTEM IN OBESITY. Journal of Neuroendocrinology, v. 20, supl. 1, p. 110–115, maio 2008.
GOJANI, Erika G. et al. ANTI-INFLAMMATORY EFFECTS OF MINOR CANNABINOIDS CBC, THCV, AND CBN IN HUMAN MACROPHAGES. Molecules, v. 28, n. 18, 2023.
HAGHDOOST, Mahan et al. TETRAHYDROCANNABIVARIN IS NOT TETRAHYDROCANNABINOL. Cannabis and Cannabinoid Research, v. 10, n. 1, p. 1–5, 2025.
JADOON, Khalid A. et al. EFFICACY AND SAFETY OF CANNABIDIOL AND TETRAHYDROCANNABIVARIN ON GLYCEMIC AND LIPID PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PILOT STUDY. Diabetes Care, v. 39, n. 10, p. 1777–1786, 2016.
KOWALCZUK, Anna et al. TETRAHYDROCANNABIVARIN (THCV) PROTECTS ADIPOSE-DERIVED MESENCHYMAL STEM CELLS (ASC) AGAINST ENDOPLASMIC RETICULUM STRESS DEVELOPMENT AND REDUCES INFLAMMATION DURING ADIPOGENESIS. International Journal of Molecular Sciences, v. 24, n. 8, 2023.
MAZIER, William et al. THE ENDOCANNABINOID SYSTEM: PIVOTAL ORCHESTRATOR OF OBESITY AND METABOLIC DISEASE. Trends in Endocrinology and Metabolism, v. 26, n. 10, p. 524–537, out. 2015.
MENDOZA, Sofia. THE ROLE OF TETRAHYDROCANNABIVARIN (THCV) IN METABOLIC DISORDERS: A PROMISING CANNABINOID FOR DIABETES AND WEIGHT MANAGEMENT. AIMS Neuroscience, v. 12, n. 1, p. 32–43, 2025.
MEYE, Frank J. et al. NEUTRAL ANTAGONISM AT THE CANNABINOID 1 RECEPTOR: A SAFER TREATMENT FOR OBESITY. Molecular Psychiatry, v. 18, n. 12, p. 1294–1301, dez. 2013.
RIEDEL, Gernot et al. SYNTHETIC AND PLANT-DERIVED CANNABINOID RECEPTOR ANTAGONISTS SHOW HYPOPHAGIC PROPERTIES IN FASTED AND NON-FASTED MICE. British Journal of Pharmacology, v. 156, n. 7, p. 1154–1166, 2009.
ROHBECK, Elena; ECKEL, Jürgen; ROMACHO, Tania. CANNABINOID RECEPTORS IN METABOLIC REGULATION AND DIABETES. Physiology, v. 36, n. 2, p. 102–113, 2021.
ROSS, A. Catharine et al. Nutrição moderna de Shils na saúde e na doença. 11. ed. São Paulo: Manole, 2016.
RUBAN, Anna et al. CURRENT TREATMENTS FOR OBESITY. Clinical Medicine, London, v. 19, n. 3, p. 205–212, maio 2019.
SIMEI, João Luís Q. et al. RESEARCH AND CLINICAL PRACTICE INVOLVING THE USE OF CANNABIS PRODUCTS, WITH EMPHASIS ON CANNABIDIOL: A NARRATIVE REVIEW. Pharmaceuticals, v. 17, n. 12, 2024.
SINGH, Kuldeep et al. EMERGING THERAPEUTIC POTENTIAL OF CANNABIDIOL (CBD) IN NEUROLOGICAL DISORDERS: A COMPREHENSIVE REVIEW. Behavioural Neurology, v. 2023, 2023.
VIANA, T. R. Xavier et al. CANNABIS MEDICINAL: UMA REVISÃO SOBRE AS PERSPECTIVAS ATUAIS E DESAFIOS FUTUROS NA PRÁTICA CLÍNICA. Journal of Research in Medicine and Health, v. 2, p. e202401, 2024.
WARGENT, Edward T. et al. THE CANNABINOID Δ(9)-TETRAHYDROCANNABIVARIN (THCV) AMELIORATES INSULIN SENSITIVITY IN TWO MOUSE MODELS OF OBESITY. Nutrition & Diabetes, v. 3, n. 5, p. e68, 2013.
WORLD HEALTH ORGANIZATION. Obesity and overweight. Geneva: WHO, 2024. Disponível em: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Acesso em: 19 set. 2025.
